May 2008 Volume 4, Issue 5
Volume 4, Issue 5 | May 2008
May 2008
In this Issue
Genomics & Proteomics

Exploring new territory
Celera inks two-year license agreement with Merck to develop RNAi-based therapeutics
Bringing it back home
Affymetrix extends Collaborations in Cancer Research Program to North American region
Raising hopes
Helicos enters collaboration to sequence cancer-associated genes
American Peptide launches new program
Company looks toward more consultative roleResearch & Development

Synthetic biology gets a boost
Codon Devices to engineer protein drug for Merrimack Pharmaceuticals
Building better bones
Merck, Harvard to advance osteoporosis research
NIEHS, U. Minn. study may lead to improved epilepsy treatments
Researchers from the National Institute of Environmental Health Sciences (NIEHS) and the University of Minnesota have gained new insight into one of the most puzzling aspects of epilepsy treatment: why some epileptics fail to respond to anti-epileptic medications.
Partners in Parkinson’s
Buck Institute and Q Therapeutics form stem cell collaboration to combat Parkinson’s DiseaseGlobal News

Collaboration is easy on the eyes
Jerini Ophthalmic and PR Pharmaceuticals to develop sustained-release formulations for eye diseasesInformatics

VERTICAL*I GOES LATERAL
Company joins forces with Thomson Scientific to provide end-to-end solutions for business development
Pfizer picks pathway partner
Ingenuity Systems to implement integrated IPA software for pharma giant
Virtual diabetes research
ADA and Entelos open access to in silico testing with virtual miceAutomation & Instrumentation

Comprehensive custom services
PerkinElmer, Cerep team up to market assay development, screening services
A “mito” distribution deal
Invitrogen gets exclusive distribution rights for MitoSciences’ monoclonal antibodies and immunoassays
Member benefits
Pennsylvania Bio inks supply deal with Fisher Scientific
ANTIBODY TRANSFER
MitoSciences gains access to University of Oregon’s monoclonal antibody portfolioEditor's Focus


Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
Subscribe